文献速递头痛与眩晕神经重症与神经感染

特发性颅内高压的核磁共振波谱代谢组学识别疾病与头痛标志物

Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache.
PubMed 文献 · Neurology · 2022-10-17

病例对照研究比较18-55岁活动期特发性颅内高压(IIH)女性与性别、年龄、体重指数匹配对照的脑脊液、血清和尿液代谢组学,IIH患者经减重干预12个月后复查。IIH患者尿素降低、乳酸:丙酮酸比值升高、乙酸升高、酮体改变,部分异常随治疗改善。

要点

  • IIH患者脑脊液和尿液尿素低于对照,且与颅内压和头痛严重程度相关。
  • IIH患者脑脊液和血清乳酸:丙酮酸比值高于对照,12个月时脑脊液该比值下降。
  • IIH患者脑脊液乙酸升高并与头痛严重程度和头痛残疾相关,12个月时降低。

核心结论

  • IIH患者脑脊液、血清和尿液存在代谢紊乱,提示全身性代谢失调。
  • 酮体代谢物改变在治疗性减重后恢复正常。
  • 脑脊液:血清尿素比值改变,可能影响颅内压动态和头痛。
  • 脑脊液乙酸升高与头痛发病率相关,这些IIH特异性代谢通路改变提供生物学见解并需机制评估。

研究设计与样本

  • 病例对照研究,比较18-55岁活动期IIH女性(Friedman诊断标准)与性别、年龄、体重指数匹配的对照组。
  • IIH参与者来自国家卫生服务机构医院的神经科和眼科门诊,接受前瞻性干预通过减重诱导疾病缓解,并在12个月时重新评估。
  • 临床评估包括腰椎穿刺、头痛、视乳头水肿和视力测量,使用质子核磁共振波谱获取脑脊液、血清和尿液代谢物光谱。

主要发现

  • 尿素在IIH参与者中较低:脑脊液对照组中位数±IQR 0.196±0.008 vs IIH 0.058±0.059,p<0.001;尿液对照组5971.370±3021.831 vs IIH 4691.363±1955.774,p=0.009。
  • 尿素与颅内压相关(尿液p=0.019)和头痛严重程度相关(脑脊液p=0.031),并在12个月时增加(脑脊液12个月0.175±0.043,p=0.004;尿液5210.874±1825.302,p=0.043)。
  • 乳酸:丙酮酸比值在IIH参与者中升高:脑脊液对照组49.739±19.523 vs IIH 113.114±117.298,p=0.023;血清对照组38.187±13.392 vs IIH 54.547±18.471,p=0.004,并在12个月时下降(脑脊液113.114±117.298,p<0.001)。
  • 基线乙酸在IIH参与者中较高:脑脊液对照组0.128±0.041 vs IIH 0.192±0.151,p=0.008,与头痛严重程度相关(p=0.030)和头痛残疾相关(p=0.003),并在12个月时降低(0.160±0.060,p=0.007)。
  • 酮体3-羟基丁酸和乙酰乙酸在基线时IIH参与者脑脊液中改变:3-羟基丁酸对照组0.074±0.063 vs IIH 0.049±0.055,p=0.019;乙酰乙酸对照组0.013±0.007 vs IIH 0.017±0.010,p=0.013,并在12个月时正常化(分别为0.112±0.114,p=0.019;0.029±0.017,p=0.015)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: We evaluated the metabolomic profile in the CSF, serum, and urine of participants with idiopathic intracranial hypertension (IIH) compared with that in controls and measured changes in metabolism associated with clinical markers of disease activity and treatment. METHODS: A case-control study compared women aged 18-55 years with active IIH (Friedman diagnostic criteria) with a sex-matched, age-matched, and body mass index-matched control group. IIH participants were identified from neurology and ophthalmology clinics from National Health Service hospitals and underwent a prospective intervention to induce disease remission through weight loss with reevaluation at 12 months. Clinical assessments included lumbar puncture, headache, papilledema, and visual measurements. Spectra of the CSF, serum, and urine metabolites were acquired using proton nuclear magnetic resonance spectroscopy. RESULTS: Urea was lower in IIH participants (CSF, controls median ± IQR 0.196 ± 0.008, IIH 0.058 ± 0.059, p < 0.001; urine, controls 5971.370 ± 3021.831, IIH 4691.363 ± 1955.774, p = 0.009), correlated with ICP (urine p = 0.019) and headache severity (CSF p = 0.031), and increased by 12 months (CSF 12 months; 0.175 ± 0.043, p = 0.004, urine; 5210.874 ± 1825.302, p = 0.043). The lactate:pyruvate ratio was increased in IIH participants compared with that in controls (CSF, controls 49.739 ± 19.523, IIH 113.114 ± 117.298, p = 0.023; serum, controls 38.187 ± 13.392, IIH 54.547 ± 18.471, p = 0.004) and decreased at 12 months (CSF, 113.114 ± 117.298, p < 0.001). Baseline acetate was higher in IIH participants (CSF, controls 0.128 ± 0.041, IIH 0.192 ± 0.151, p = 0.008), correlated with headache severity (p = 0.030) and headache disability (p = 0.003), and was reduced at 12 months (0.160 ± 0.060, p = 0.007). Ketones, 3-hydroxybutyrate and acetoacetate, were altered in the CSF at baseline in IIH participants (3-hydroxybutyrate, controls 0.074 ± 0.063, IIH 0.049 ± 0.055, p = 0.019; acetoacetate, controls 0.013 ± 0.007, IIH 0.017 ± 0.010, p = 0.013) and normalized at 12 months (0.112 ± 0.114, p = 0.019, 0.029 ± 0.017, p = 0.015, respectively). DISCUSSION: We observed metabolic disturbances that are evident in the CSF, serum, and urine of IIH participants, suggesting global metabolic dysregulation. Altered ketone body metabolites normalized after therapeutic weight loss. CSF:serum urea ratio was altered, which may influence ICP dynamics and headache. Elevated CSF acetate, known to stimulate trigeminal sensitization, was associated with headache morbidity. These alterations of metabolic pathways specific to IIH provide biological insight and warrant mechanistic evaluation. TRIAL REGISTRATION INFORMATION: Registered on ClinicalTrials.gov, NCT02124486 (submitted April 22, 2014) and NCT02017444 (submitted December 16, 2013).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Grech O, Seneviratne SY, Alimajstorovic Z, et al. Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache. Neurology. 2022. PMID: 36240084. doi:10.1212/WNL.0000000000201007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。